Amgen Inc.
AMGNAmgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
Drugs in Pipeline
216
Phase 3 Programs
127
Upcoming Catalysts
13
Next Catalyst
Aug 4, 2026
4wMarket Overview
Stock performance and key metrics
13 upcoming, 4 past
How AMGN's past catalysts played out
Lumakras
Sotorasib
KRAS G12C NSCLC
Trifluridine and Tipiracil
Colorectal Cancer (CRC)
Apremilast (CC-10004)
Behcet Syndrome
Topical Therapy
Plaque Psoriasis
Vincrisitne
Leukemia, Acute Lymphoblastic
Lanadelumab
COVID-19
FOLFOX regimen
Metastatic Colorectal Cancer
RP103
Cystinosis
Blinatumomab
Acute Lymphoblastic Leukemia
Adalimumab
Plaque Psoriasis
AMG 073
Secondary Hyperparathyroidism
Aranesp®
Kidney Disease
rHuEPO
Cancer
Apremilast 20mg
Psoriatic Arthritis
Evolocumab AMD
Primary Hypercholesterolemia
Abiraterone
Metastatic Castration-resistant Prostate Cancer
MP-376 (Levofloxacin Solution for Inhalation)
Cystic Fibrosis
Risendronate
Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
De Novo Administration of Darbepoetin Alfa
Chronic Kidney Disease
Epoetin alfa RB
Nephrology
Actonel®
Osteoporosis
Apremilast 30mg
Psoriatic Arthritis
Background Statin Therapy
Dyslipidemia
ABP 938
Neovascular (Wet) Age-related Macular Degeneration (AMD)
darbepoetin alfa
Anemia
Cystagon®
Cystinosis
60 mg denosumab
Low Bone Mass
Lenalidomide
Relapsed Multiple Myeloma
Zoledronic Acid
Bone Metastases
Best Supportive Care
Multiple Myeloma
Denosumab
Osteoporosis
mFOLFOX6
Gastric Cancer
Aflibercept
Chorioretinal Vascular Disease
Oxaliplatin Based Chemotherapy
Colorectal Cancer
Chemotherapy
Gastric Cancer
Romosozumab 90 mg/mL
Postmenopausal Osteoporosis
Topical treatments or phototherapy
Plaque Psoriasis
Standard Chemotherapy
Cancer
romosozumab HCP administration with PFS
Post-Menopausal Osteoporosis
etanercept pre-filled syringe subcutaneous injection
Rheumatoid Arthritis
Recombinant Human Keratinocyte Growth Factor
Stomatitis
Atorvastatin
Diabetes, Hyperlipidemia, Mixed Dyslipidemia
Anakinra (Kineret®)
Rheumatoid Arthritis
Teprotumumab
Thyroid Eye Disease
1=Etanercept
Psoriasis
Apremilast 30 mg
Psoriatic Arthritis
Non-steroidal aromatase inhibitor therapy
Breast Cancer
Statin therapy
Coronary Artery Disease (CAD)
Pegloticase
Uncontrolled Gout
pegfilgrastim
Breast Cancer
Ibuprofen/famotidine
Ulcer
Inebilizumab
IgG4 Related Disease
interferon γ-1b
Friedreich's Ataxia
FOLFIRI
Metastatic Colorectal Cancer
Ocrelizumab (US)
Relapsing-remitting Multiple Sclerosis (RRMS)
ABP 234
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Ibandronate
Postmenopausal Osteoporosis
ABP 710
Arthritis, Rheumatoid
Sotorasib
Non-small Cell Lung Cancer
ABP 501
Arthritis, Rheumatoid
AMG 510
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Denosumab (AMG 162)
Postmenopausal Osteoporosis
Xaluritamig
Metastatic Castration-resistant Prostate Cancer
Olpasiran
Cardiovascular Disease
Pembrolizumab
Melanoma
Ezetimibe
Hyperlipidemia
Aranesp® (darbepoetin alfa)
Kidney Disease
Erenumab Dose 1
Migraine
Etanercept / Autoinjector A
Rheumatoid Arthritis
Denosumab (for the open-label treatment phase)
Cancer
Romiplostim
Chemotherapy-induced Thrombocytopenia
AMG 531
Thrombocytopenia
Dazodalibep
Sjögren's Syndrome (SS)
Topical agents
Psoriasis
AMG 386
Ovarian Cancer
AMG 162
Postmenopausal Osteoporosis
Cinacalcet HCl
Kidney Disease
AMG 162 / Denosumab
Breast Cancer
HPN-100
Cirrhosis
Bemarituzumab
Gastric Cancer
Cetuximab
Metastatic Colorectal Cancer
Dexamethasone
Relapsed and Refractory Multiple Myeloma
Low-intensity chemotherapy regimen
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Palifermin
Head and Neck Cancer
Etanercept
Rheumatoid Arthritis
alendronate
Osteoporosis
Erenumab
Migraine
Darbepoetin alfa - 2.25 mcg/kg
Anemia
Maridebart cafraglutide
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Cysteamine Bitartrate Delayed-release Capsules
Cystinosis
Aeroquin
Cystic Fibrosis
Commercial Formulation Etanercept
Arthritis, Rheumatoid; Arthritis, Psoriatic
ABP 959
Paroxysmal Nocturnal Hemoglobinuria
Apremilast
Behçet's Disease
Etelcalcetide
Secondary Hyperparathyroidism
Etoposide
Small-cell Lung Cancer
Panitumumab
Metastatic Colorectal Cancer
ABP 206
Melanoma
Daratumumab
Relapsed Multiple Myeloma
Cinacalcet
End Stage Renal Disease
Tarlatamab
Small Cell Lung Cancer
Cystagon® (Cysteamine Bitartrate)
Cystinosis
Methotrexate
Psoriatic Arthritis
Carfilzomib
Multiple Myeloma
Evolocumab Pre-filled Syringe
Primary Hypercholesterolemia
Evolocumab
Hyperlipidemia
Romozosumab
Postmenopausal Osteoporosis
Paclitaxel
Locally Recurrent and Metastatic Breast Cancer
darbepoetin alfa SF
Kidney Disease
Darbepoetin alfa and Epoetin alfa
Anemia
FOLFIRI Regimen
Metastatic Colorectal Cancer
Buphenyl (NaPBA)
Urea Cycle Disorders
Apremilast tablet 20 mg
Ankylosing Spondyloarthritis
MR prednisone
Rheumatoid Arthritis
HZT-501
Osteoarthritis
Avacopan
Vasculitis
Lurbinectedin
Small Cell Lung Cancer (SCLC)
Etanercept Liquid
Rheumatoid Arthritis
ABP 798
Arthritis, Rheumatoid
Bortezomib
Multiple Myeloma
50 mg Etanercept
Rheumatoid Arthritis
ABP 980
Breast Cancer
Ustekinumab
Psoriasis
Epoetin alfa DT
Chronic Kidney Disease
Romosozumab
Postmenopausal Women With Osteoporosis
Rosuvastatin
Hyperlipidemia
Rocatinlimab
Asthma
Carboplatin
Non-small Cell Lung Cancer Metastatic
Irinotecan
Metastatic Colorectal Cancer
CC10004
Psoriasis
Adecatumumab
Liver Metastases
AMG 531 (Romiplostim)
MDS
IV Bisphosphonates
Breast Cancer
Darbepoetin alfa SC
Anemia
pegfilgrastim 12 mg
Lymphoma
Sunitinib
Advanced Renal Cell Carcinoma
5-Fluorouracil
Colorectal Cancer
Panitumumab (ABX-EGF)
Advanced Renal Cell Carcinoma
AMG 853
Asthma
epratuzumab
Non-Hodgkin's Lymphoma
cinacalcet (AMG 073)
Secondary Hyperparathyroidism
VIB7734
Lupus Erythematosus, Systemic
Modified FOLFOX6
Advanced Solid Tumors
AMG 827
Asthma
IV Bisphosphonate q 4 weeks
Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Pegsunercept (PEG sTNF-RI)
Rheumatoid Arthritis
MP-376
Cystic Fibrosis (CF)
Teriparatide
Low Bone Mineral Density
CCX140-B
Diabetic Nephropathy
AMG 102 at 10 mg/kg
Advanced Renal Cell Carcinoma
AMG 655
Metastatic Colorectal Cancer
BUPHENYL®
Urea Cycle Disorders
CCX-354-C
Rheumatoid Arthritis
100 mg AMG 162
Osteoporosis
filgrastim
Sarcoma
ABX-EGF
Non-small Cell Lung Cancer
VIB4920
Sjögren's Syndrome
Belatacept
Allografts
Conatumumab
Colon Cancer
cyclophosphamide
Breast Cancer
AMG 714
Psoriasis
AMG 719
Rheumatoid Arthritis
AMG 732
Thyroid Eye Disease
Abrilumab
Ulcerative Colitis
Brodalumab
Rheumatoid Arthritis
Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
Anemia
Tezepelumab Dose 1
Chronic Spontaneous Urticaria
Recombinant Human Erythropoietin
Breast Cancer
Rozibafusp Alfa
Systemic Lupus Erythematosus (SLE)
CCX168
Vasculitis
ABX-EGF (panitumumab)
Metastatic Colorectal Cancer
IDE397
MTAP-null Non-Small-Cell Lung Cancer
recombinant human erythropoietin (rHuEPO)
Gynecological Malignancies
AMG 951 (rhApo2L/TRAIL)
Non-Small Cell Lung Cancer
HZN-1116
Sjogren's Syndrome
Gemcitabine
Lung Cancer
Cisplatin
Squamous Cell Carcinoma of Head and Neck
pioglitazone
Type 2 Diabetes Mellitus
Talimogene laherparepvec
Melanoma
AMG 193
MTAP-deleted NSCLC
Systemic AMG 108
Osteoarthritis
Blinatumomab (MT103)
Acute Lymphoblastic Leukemia
anakinra
Rheumatoid Arthritis
Capecitabine
Esophagogastric Junction Adenocarcinoma
AMG 317 75 mg
Asthma
Liatermin
Parkinson's Disease
Daxdilimab
Alopecia Areata
AMG 151
Diabetes Mellitus
Intra-articular metHuIL-1ra (anakinra)
Osteoarthritis
Docetaxel
Advanced MTAP-null Solid Tumors
IV iron dextran
Anemia
Pemetrexed
Non Small Cell Lung Cancer
Neulasta
Breast Cancer
Erenumab PFS
Migraine
AMG 102 at 20 mg/kg
Advanced Malignant Glioma
CCX 354-C
Rheumatoid Arthritis
AMG 706
Gastrointestinal Cancer
AMG 337
Stomach Neoplasms
Apremilast 10mg
Psoriasis
AMG 386 10mg/kg
Gastrointestinal Cancer
Pomalidomide
Relapsed or Refractory Multiple Myeloma
Naproxen
Bone Pain in Stage I - III Breast Cancer
CC-10004
Psoriasis
Oprozomib
Multiple Myeloma
Previous denosumab
Low Bone Mass
Sensipar (Cinacalcet HCl)
Secondary Hyperparathyroidism
AMG 301
Chronic Migraine or Episodic Migraine
AMG 108
Rheumatoid Arthritis
Sorafenib
Advanced Hepatocellular Carcinoma
Lodotra
Asthma
CCX282-B
Crohn's Disease
AMG 223
End Stage Renal Disease
NaPBA
Urea Cycle Disorders
Motesanib diphosphate
Lung Cancer
AMG 102
Cancer
AMG 509
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lumakras Sotorasib | Approved | KRAS G12C NSCLC | Fast TrackBreakthrough | Patent 2040 |
Trifluridine and Tipiracil | Phase 3 | Colorectal Cancer (CRC) | - | - |
Apremilast (CC-10004) | Phase 3 | Behcet Syndrome | - | - |
Topical Therapy | Phase 3 | Plaque Psoriasis | - | - |
Vincrisitne | Phase 3 | Leukemia, Acute Lymphoblastic | - | - |
Lanadelumab | Phase 3 | COVID-19 | - | - |
FOLFOX regimen | Phase 3 | Metastatic Colorectal Cancer | - | - |
RP103 | Phase 3 | Cystinosis | - | - |
Blinatumomab | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
Adalimumab | Phase 3 | Plaque Psoriasis | - | - |
AMG 073 | Phase 3 | Secondary Hyperparathyroidism | - | - |
Aranesp® | Phase 3 | Kidney Disease | - | - |
rHuEPO | Phase 3 | Cancer | - | - |
Apremilast 20mg | Phase 3 | Psoriatic Arthritis | - | - |
Evolocumab AMD | Phase 3 | Primary Hypercholesterolemia | - | - |
Abiraterone | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
MP-376 (Levofloxacin Solution for Inhalation) | Phase 3 | Cystic Fibrosis | - | - |
Risendronate | Phase 3 | Steroid-induced Osteopor, Glucocorticoid-induced Ostepor | - | - |
De Novo Administration of Darbepoetin Alfa | Phase 3 | Chronic Kidney Disease | - | - |
Epoetin alfa RB | Phase 3 | Nephrology | - | - |
Actonel® | Phase 3 | Osteoporosis | - | - |
Apremilast 30mg | Phase 3 | Psoriatic Arthritis | - | - |
Background Statin Therapy | Phase 3 | Dyslipidemia | - | - |
ABP 938 | Phase 3 | Neovascular (Wet) Age-related Macular Degeneration (AMD) | - | - |
darbepoetin alfa | Phase 3 | Anemia | - | - |
Cystagon® | Phase 3 | Cystinosis | - | - |
60 mg denosumab | Phase 3 | Low Bone Mass | - | - |
Lenalidomide | Phase 3 | Relapsed Multiple Myeloma | - | - |
Zoledronic Acid | Phase 3 | Bone Metastases | - | - |
Best Supportive Care | Phase 3 | Multiple Myeloma | - | - |
Denosumab | Phase 3 | Osteoporosis | - | - |
mFOLFOX6 | Phase 3 | Gastric Cancer | - | - |
Aflibercept | Phase 3 | Chorioretinal Vascular Disease | - | - |
Oxaliplatin Based Chemotherapy | Phase 3 | Colorectal Cancer | - | - |
Chemotherapy | Phase 3 | Gastric Cancer | - | - |
Romosozumab 90 mg/mL | Phase 3 | Postmenopausal Osteoporosis | - | - |
Topical treatments or phototherapy | Phase 3 | Plaque Psoriasis | - | - |
Standard Chemotherapy | Phase 3 | Cancer | - | - |
romosozumab HCP administration with PFS | Phase 3 | Post-Menopausal Osteoporosis | - | - |
etanercept pre-filled syringe subcutaneous injection | Phase 3 | Rheumatoid Arthritis | - | - |
Recombinant Human Keratinocyte Growth Factor | Phase 3 | Stomatitis | - | - |
Atorvastatin | Phase 3 | Diabetes, Hyperlipidemia, Mixed Dyslipidemia | - | - |
Anakinra (Kineret®) | Phase 3 | Rheumatoid Arthritis | - | - |
Teprotumumab | Phase 3 | Thyroid Eye Disease | - | - |
1=Etanercept | Phase 3 | Psoriasis | - | - |
Apremilast 30 mg | Phase 3 | Psoriatic Arthritis | - | - |
Non-steroidal aromatase inhibitor therapy | Phase 3 | Breast Cancer | - | - |
Statin therapy | Phase 3 | Coronary Artery Disease (CAD) | - | - |
Pegloticase | Phase 3 | Uncontrolled Gout | - | - |
pegfilgrastim | Phase 3 | Breast Cancer | - | - |
Ibuprofen/famotidine | Phase 3 | Ulcer | - | - |
Inebilizumab | Phase 3 | IgG4 Related Disease | - | - |
interferon γ-1b | Phase 3 | Friedreich's Ataxia | - | - |
FOLFIRI | Phase 3 | Metastatic Colorectal Cancer | - | - |
Ocrelizumab (US) | Phase 3 | Relapsing-remitting Multiple Sclerosis (RRMS) | - | - |
ABP 234 | Phase 3 | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | - | - |
Ibandronate | Phase 3 | Postmenopausal Osteoporosis | - | - |
ABP 710 | Phase 3 | Arthritis, Rheumatoid | - | - |
Sotorasib | Phase 3 | Non-small Cell Lung Cancer | - | - |
ABP 501 | Phase 3 | Arthritis, Rheumatoid | - | - |
AMG 510 | Phase 3 | KRAS p, G12c Mutated /Advanced Metastatic NSCLC | - | - |
Denosumab (AMG 162) | Phase 3 | Postmenopausal Osteoporosis | - | - |
Xaluritamig | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
Olpasiran | Phase 3 | Cardiovascular Disease | - | - |
Pembrolizumab | Phase 3 | Melanoma | - | - |
Ezetimibe | Phase 3 | Hyperlipidemia | - | - |
Aranesp® (darbepoetin alfa) | Phase 3 | Kidney Disease | - | - |
Erenumab Dose 1 | Phase 3 | Migraine | - | - |
Etanercept / Autoinjector A | Phase 3 | Rheumatoid Arthritis | - | - |
Denosumab (for the open-label treatment phase) | Phase 3 | Cancer | - | - |
Romiplostim | Phase 3 | Chemotherapy-induced Thrombocytopenia | - | - |
AMG 531 | Phase 3 | Thrombocytopenia | - | - |
Dazodalibep | Phase 3 | Sjögren's Syndrome (SS) | - | - |
Topical agents | Phase 3 | Psoriasis | - | - |
AMG 386 | Phase 3 | Ovarian Cancer | - | - |
AMG 162 | Phase 3 | Postmenopausal Osteoporosis | - | - |
Cinacalcet HCl | Phase 3 | Kidney Disease | - | - |
AMG 162 / Denosumab | Phase 3 | Breast Cancer | - | - |
HPN-100 | Phase 3 | Cirrhosis | - | - |
Bemarituzumab | Phase 3 | Gastric Cancer | - | - |
Cetuximab | Phase 3 | Metastatic Colorectal Cancer | - | - |
Dexamethasone | Phase 3 | Relapsed and Refractory Multiple Myeloma | - | - |
Low-intensity chemotherapy regimen | Phase 3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | - | - |
Palifermin | Phase 3 | Head and Neck Cancer | - | - |
Etanercept | Phase 3 | Rheumatoid Arthritis | - | - |
alendronate | Phase 3 | Osteoporosis | - | - |
Erenumab | Phase 3 | Migraine | - | - |
Darbepoetin alfa - 2.25 mcg/kg | Phase 3 | Anemia | - | - |
Maridebart cafraglutide | Phase 3 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | - | - |
Cysteamine Bitartrate Delayed-release Capsules | Phase 3 | Cystinosis | - | - |
Aeroquin | Phase 3 | Cystic Fibrosis | - | - |
Commercial Formulation Etanercept | Phase 3 | Arthritis, Rheumatoid; Arthritis, Psoriatic | - | - |
ABP 959 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Apremilast | Phase 3 | Behçet's Disease | - | - |
Etelcalcetide | Phase 3 | Secondary Hyperparathyroidism | - | - |
Etoposide | Phase 3 | Small-cell Lung Cancer | - | - |
Panitumumab | Phase 3 | Metastatic Colorectal Cancer | - | - |
ABP 206 | Phase 3 | Melanoma | - | - |
Daratumumab | Phase 3 | Relapsed Multiple Myeloma | - | - |
Cinacalcet | Phase 3 | End Stage Renal Disease | - | - |
Tarlatamab | Phase 3 | Small Cell Lung Cancer | OrphanFast TrackBreakthrough | |
Cystagon® (Cysteamine Bitartrate) | Phase 3 | Cystinosis | - | - |
Methotrexate | Phase 3 | Psoriatic Arthritis | - | - |
Carfilzomib | Phase 3 | Multiple Myeloma | - | - |
Evolocumab Pre-filled Syringe | Phase 3 | Primary Hypercholesterolemia | - | - |
Evolocumab | Phase 3 | Hyperlipidemia | - | - |
Romozosumab | Phase 3 | Postmenopausal Osteoporosis | - | - |
Paclitaxel | Phase 3 | Locally Recurrent and Metastatic Breast Cancer | - | - |
darbepoetin alfa SF | Phase 3 | Kidney Disease | - | - |
Darbepoetin alfa and Epoetin alfa | Phase 3 | Anemia | - | - |
FOLFIRI Regimen | Phase 3 | Metastatic Colorectal Cancer | - | - |
Buphenyl (NaPBA) | Phase 3 | Urea Cycle Disorders | - | - |
Apremilast tablet 20 mg | Phase 3 | Ankylosing Spondyloarthritis | - | - |
MR prednisone | Phase 3 | Rheumatoid Arthritis | - | - |
HZT-501 | Phase 3 | Osteoarthritis | - | - |
Avacopan | Phase 3 | Vasculitis | - | - |
Lurbinectedin | Phase 3 | Small Cell Lung Cancer (SCLC) | - | - |
Etanercept Liquid | Phase 3 | Rheumatoid Arthritis | - | - |
ABP 798 | Phase 3 | Arthritis, Rheumatoid | - | - |
Bortezomib | Phase 3 | Multiple Myeloma | - | - |
50 mg Etanercept | Phase 3 | Rheumatoid Arthritis | - | - |
ABP 980 | Phase 3 | Breast Cancer | - | - |
Ustekinumab | Phase 3 | Psoriasis | - | - |
Epoetin alfa DT | Phase 3 | Chronic Kidney Disease | - | - |
Romosozumab | Phase 3 | Postmenopausal Women With Osteoporosis | - | - |
Rosuvastatin | Phase 3 | Hyperlipidemia | - | - |
Rocatinlimab | Phase 3 | Asthma | - | - |
Carboplatin | Phase 3 | Non-small Cell Lung Cancer Metastatic | - | - |
Irinotecan | Phase 2 | Metastatic Colorectal Cancer | - | - |
CC10004 | Phase 2 | Psoriasis | - | - |
Adecatumumab | Phase 2 | Liver Metastases | - | - |
AMG 531 (Romiplostim) | Phase 2 | MDS | - | - |
IV Bisphosphonates | Phase 2 | Breast Cancer | - | - |
Darbepoetin alfa SC | Phase 2 | Anemia | - | - |
pegfilgrastim 12 mg | Phase 2 | Lymphoma | - | - |
Sunitinib | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
5-Fluorouracil | Phase 2 | Colorectal Cancer | - | - |
Panitumumab (ABX-EGF) | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
AMG 853 | Phase 2 | Asthma | - | - |
epratuzumab | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
cinacalcet (AMG 073) | Phase 2 | Secondary Hyperparathyroidism | - | - |
VIB7734 | Phase 2 | Lupus Erythematosus, Systemic | - | - |
Modified FOLFOX6 | Phase 2 | Advanced Solid Tumors | - | - |
AMG 827 | Phase 2 | Asthma | - | - |
IV Bisphosphonate q 4 weeks | Phase 2 | Bone Metastases in Men With Hormone-Refractory Prostate Cancer | - | - |
Pegsunercept (PEG sTNF-RI) | Phase 2 | Rheumatoid Arthritis | - | - |
MP-376 | Phase 2 | Cystic Fibrosis (CF) | - | - |
Teriparatide | Phase 2 | Low Bone Mineral Density | - | - |
CCX140-B | Phase 2 | Diabetic Nephropathy | - | - |
AMG 102 at 10 mg/kg | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
AMG 655 | Phase 2 | Metastatic Colorectal Cancer | - | - |
BUPHENYL® | Phase 2 | Urea Cycle Disorders | - | - |
CCX-354-C | Phase 2 | Rheumatoid Arthritis | - | - |
100 mg AMG 162 | Phase 2 | Osteoporosis | - | - |
filgrastim | Phase 2 | Sarcoma | - | - |
ABX-EGF | Phase 2 | Non-small Cell Lung Cancer | - | - |
VIB4920 | Phase 2 | Sjögren's Syndrome | - | - |
Belatacept | Phase 2 | Allografts | - | - |
Conatumumab | Phase 2 | Colon Cancer | - | - |
cyclophosphamide | Phase 2 | Breast Cancer | - | - |
AMG 714 | Phase 2 | Psoriasis | - | - |
AMG 719 | Phase 2 | Rheumatoid Arthritis | - | - |
AMG 732 | Phase 2 | Thyroid Eye Disease | - | - |
Abrilumab | Phase 2 | Ulcerative Colitis | - | - |
Brodalumab | Phase 2 | Rheumatoid Arthritis | - | - |
Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa) | Phase 2 | Anemia | - | - |
Tezepelumab Dose 1 | Phase 2 | Chronic Spontaneous Urticaria | - | - |
Recombinant Human Erythropoietin | Phase 2 | Breast Cancer | - | - |
Rozibafusp Alfa | Phase 2 | Systemic Lupus Erythematosus (SLE) | - | - |
CCX168 | Phase 2 | Vasculitis | - | - |
ABX-EGF (panitumumab) | Phase 2 | Metastatic Colorectal Cancer | - | - |
IDE397 | Phase 2 | MTAP-null Non-Small-Cell Lung Cancer | - | - |
recombinant human erythropoietin (rHuEPO) | Phase 2 | Gynecological Malignancies | - | - |
AMG 951 (rhApo2L/TRAIL) | Phase 2 | Non-Small Cell Lung Cancer | - | - |
HZN-1116 | Phase 2 | Sjogren's Syndrome | - | - |
Gemcitabine | Phase 2 | Lung Cancer | - | - |
Cisplatin | Phase 2 | Squamous Cell Carcinoma of Head and Neck | - | - |
pioglitazone | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Talimogene laherparepvec | Phase 2 | Melanoma | - | - |
AMG 193 | Phase 2 | MTAP-deleted NSCLC | - | - |
Systemic AMG 108 | Phase 2 | Osteoarthritis | - | - |
Blinatumomab (MT103) | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
anakinra | Phase 2 | Rheumatoid Arthritis | - | - |
Capecitabine | Phase 2 | Esophagogastric Junction Adenocarcinoma | - | - |
AMG 317 75 mg | Phase 2 | Asthma | - | - |
Liatermin | Phase 2 | Parkinson's Disease | - | - |
Daxdilimab | Phase 2 | Alopecia Areata | - | - |
AMG 151 | Phase 2 | Diabetes Mellitus | - | - |
Intra-articular metHuIL-1ra (anakinra) | Phase 2 | Osteoarthritis | - | - |
Docetaxel | Phase 2 | Advanced MTAP-null Solid Tumors | - | - |
IV iron dextran | Phase 2 | Anemia | - | - |
Pemetrexed | Phase 2 | Non Small Cell Lung Cancer | - | - |
Neulasta | Phase 2 | Breast Cancer | - | - |
Erenumab PFS | Phase 2 | Migraine | - | - |
AMG 102 at 20 mg/kg | Phase 2 | Advanced Malignant Glioma | - | - |
CCX 354-C | Phase 2 | Rheumatoid Arthritis | - | - |
AMG 706 | Phase 2 | Gastrointestinal Cancer | - | - |
AMG 337 | Phase 2 | Stomach Neoplasms | - | - |
Apremilast 10mg | Phase 2 | Psoriasis | - | - |
AMG 386 10mg/kg | Phase 2 | Gastrointestinal Cancer | - | - |
Pomalidomide | Phase 2 | Relapsed or Refractory Multiple Myeloma | - | - |
Naproxen | Phase 2 | Bone Pain in Stage I - III Breast Cancer | - | - |
CC-10004 | Phase 2 | Psoriasis | - | - |
Oprozomib | Phase 2 | Multiple Myeloma | - | - |
Previous denosumab | Phase 2 | Low Bone Mass | - | - |
Sensipar (Cinacalcet HCl) | Phase 2 | Secondary Hyperparathyroidism | - | - |
AMG 301 | Phase 2 | Chronic Migraine or Episodic Migraine | - | - |
AMG 108 | Phase 2 | Rheumatoid Arthritis | - | - |
Sorafenib | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
Lodotra | Phase 2 | Asthma | - | - |
CCX282-B | Phase 2 | Crohn's Disease | - | - |
AMG 223 | Phase 2 | End Stage Renal Disease | - | - |
NaPBA | Phase 2 | Urea Cycle Disorders | - | - |
Motesanib diphosphate | Phase 2 | Lung Cancer | - | - |
AMG 102 | Phase 2 | Cancer | - | - |
AMG 509 | Phase 1 | Prostate Cancer | Fast Track | - |
KRAS G12C NSCLC
1 drug in this indication
Small Cell Lung Cancer
1 drug in this indication
Prostate Cancer
1 drug in this indication
Systemic Lupus Erythematosus (SLE)
1 drug in this indication
Rheumatoid Arthritis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Amgen Inc.'s drug pipeline?→
CatalystAlert tracks 216 drug candidates in Amgen Inc.'s (AMGN) pipeline across Phase 3, Phase 2, Phase 1, Approved. Its lead program is Trifluridine and Tipiracil (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Amgen Inc.'s next FDA catalyst?→
Amgen Inc.'s (AMGN) next tracked catalyst is a Phase 2 expected July 2, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AMGN biotech catalysts?→
Add AMGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Amgen Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.